Beta Bionics (BBNX)
Builds the iLet automated insulin delivery system for type 1 diabetes.
$23.04
vs last close+0.23 (+1.00%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 107.47% | 48.35M shares | |
|---|---|---|---|
| 138 holders · as of Jun 30, 2026 | |||
| Insiders | 2.70% | 1.21M shares | |
| 11 holders · as of Sep 18, 2026 | |||
| Strategic holders | 5.69% | 2.56M shares | |
| 1 holder · as of May 12, 2026 | |||
| Adds to | 115.86% | ||
44.99M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 115.86%; nothing is left for Other.
13F, as of Jun 30, 2026
138 holders · 48.35M shares · 32 new positions · 90 increased · 35 reduced · 25 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Eventide Asset Management, LLC | 6.25M | 13.90% | +308.2K | Aug 14, 2026 |
| Soleus Capital Management, L.P. | 4.39M | 9.77% | +39.2K | Aug 11, 2026 |
| Morgan Stanley | 4.27M | 9.48% | +39.2K | Aug 13, 2026 |
| Sands Capital Ventures, LLC | 3.71M | 8.24% | 0 | Aug 13, 2026 |
| BlackRock, Inc. | 3.34M | 7.42% | +301.6K | Aug 7, 2026 |
| Point72 Asset Management, L.P. | 2.25M | 5.01% | −270.4K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.78M | 3.96% | +54.4K | Aug 13, 2026 |
| Vestal Point Capital, LP | 1.60M | 3.56% | −611.5K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Eventide Asset Management, LLC | 13.40% | 5.95M | 13G | May 15, 2026 |
| Morgan Stanley | 8.60% | 3.74M | 13G | Nov 7, 2025 |
| Sands Capital Life Sciences Pulse Fund II. L.P. | 8.20% | 3.57M | 13G | Aug 13, 2025 |
| Divisadero Street Capital Management, LP | 6.90% | 3.07M | 13G | Jul 24, 2026 |
| BlackRock, Inc. | 6.40% | 2.78M | 13G | Oct 17, 2025 |
| Zone Healthcare Holdings, LLC | 5.80% | 2.56M | 13G | May 12, 2026 |
| Point72 Asset Management, L.P. | 5.20% | 2.29M | 13G | Feb 23, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 9, 2026 | Mark Hopmanofficer: Chief Commercial Officer | Sale · 2 lots | 72,864 | $18.46 | 87,157 |
| Sep 16, 2026 | Mike Mensingerofficer: Chief Product Officer | Sale | 2,650 | $22.00 | 177,390 |
| Sep 16, 2026 | Mark Hopmanofficer: Chief Commercial Officer | Sale | 30,779 | $20.13 | 56,479 |
| Sep 14, 2026 | Mark Hopmanofficer: Chief Commercial Officer | Sale | 775 | $15.52 | 86,382 |
| Sep 3, 2026 | Sean Saintdirector, officer: President & CEO | Sale | 5,641 | $20.08 | 398,429 |
| Sep 2, 2026 | Sean Saintdirector, officer: President & CEO | Sale | 16,867 | $19.11 | 404,070 |
| Sep 2, 2026 | Stephen Feiderofficer: Chief Financial Officer | Sale | 6,675 | $19.11 | 159,378 |
| Sep 2, 2026 | Mike Mensingerofficer: Chief Product Officer | Sale | 4,375 | $19.11 | 180,040 |
| Sep 2, 2026 | Steven Jon Russellofficer: Chief Medical Officer | Sale | 4,221 | $19.11 | 169,628 |
| Sep 2, 2026 | Mark Hopmanofficer: Chief Commercial Officer | Sale | 5,327 | $19.11 | 124,027 |
House and Senate disclosures
Not reported.